- New clinical data confirm the good tolerance of CoVepiT and a very good level of T cell response in healthy volunteers vaccinated.
- Promising preclinical efficacy signals guide development in immunocompromised patients with poor antibody response to present registered anti-COVID vaccines.
- Results on the 6-month long-term memory T response, expected in the first quarter of 2022, will be a key element in further clinical development.
- CoVepiT epitopes* remain independent of mutations identified in current and emerging variants.
NANTES,
Last July, the company voluntarily suspended the recruitment and administration of CoVepiT in the Phase 1 clinical trial as a precaution due to a limited number of adverse reactions (nodule-like indurations at the injection site) grade 1 and a grade 2 adverse reaction in one participant. Since then, the data have been analyzed regularly with the Independent Safety Monitoring Committee in charge of evaluating the safety of the trial and the Ghent (
The immunological response was measured on the eight healthy volunteers who received CoVepiT, showing the expected efficacy at six weeks after the injection, the primary endpoint of the phase 1 trial, with good immunogenicity of the T cells against the viral epitopes. Interferon-gamma responses measured by Elispot was observed in 100% of participants, from the 22nd day to the 6th week. These immunological results are significantly better than those obtained in convalescent patients and confirm the interest and the mechanism of action of the vaccine on the T cell response.
In addition, new preclinical studies have shown that the intensity and the quality of the immunogenicity of the T cells induced by the CoVepiT vaccine were not altered by concomitant immunosuppressive treatments such as antimetabolites (mycophenolate mofetil, MMF, inhibiting immunosuppressant proliferation of B and T cells) or by a strong depletion of B cells producing antibodies (observed with rituximab, used in autoimmune diseases and certain cancers). The interest in generating T cells is enhanced especially for immunocompromised patients with weak antibody responses despite repeated administration of current registered vaccines.
Alexis Peyroles, CEO of
This therapeutic approach of modified epitopes has already enabled us to obtain a T response against tumor antigens in oncology, resulting in a significant benefit in terms of survival for our Tedopi® product in advanced non -small cell lung cancer patients (NSCLC) with secondary resistance to immunotherapy (
*These epitopes, fragments of viral proteins, are antigenic determinants recognized by T cell receptors during an adaptive T immune response. They are not currently impacted by the mutations described for the existing variants (Delta) and emergent variants (Omicron).
(1) Pleguezuelos et al. 2020
(2) Rodo et al. PLoS Pathog 2019
(3) Heitmann, J. S. et al. Nature 2021
ABOUT CoVepiT
CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as well as those of previous human-infective CoVs, SARS and MERS, to identify vaccine targets with the lowest chance of natural mutation. Targeting 11 virus proteins including Spike, M, N and several non-structural proteins, this second-generation vaccine covers all initial and novel SARS-CoV-2 variants identified globally to date. In preclinical testing, CoVepiT demonstrated the ability to activate T cell defenses through CD8 T-cell multi-epitope responses for long-term T memory cell immunity.
ABOUT
Vaccine platform
- Tedopi® (innovative combination of neoepitopes): the company’s most advanced product; positive results for Phase 3 trial (
Atalante 1) in Non-Small CellLung Cancer patients after secondary resistance to checkpoint inhibitors.
In Phase 2 in pancreatic cancer (TEDOPaM), sponsor GERCOR.
In Phase 2 in ovary cancer, in combination with pembrolizumab (TEDOVA), sponsor ARCAGY-GINECO.
In Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT. - CoVepiT: a prophylactic second-generation vaccine against COVID-19, developed using SARS-CoV-2 optimized epitopes against multi variants. Positive preclinical and human ex vivo results. Voluntary and temporary Phase 1 enrollment suspension on-going (July 2021).
- BI 765063 (OSE-172, anti-SIRPα mAb on CD47/SIRPα pathway): developed in partnership with
Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results of BI 765063 in monotherapy or in combination with ezabenlimab (PD-1 antagonist); Expansion Phase 1 open for screening. - CLEC-1 (novel myeloid checkpoint target): identification of mAb antagonists of CLEC-1 blocking the “Don’t Eat Me” signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells.
- BiCKI®: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity.
Auto-immunity and inflammation platform
- FR104 (anti-CD28 monoclonal antibody): Licensing partnership agreement with Veloxis in the organ transplant market; ongoing Phase 1/2 in renal transplant (sponsored by the
Nantes University Hospital ); Phase 2-ready asset in an autoimmune disease indication. - OSE-127/S95011 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with
Servier ; positive Phase 1 results; in Phase 2 in ulcerative colitis (OSE sponsor) and an independent Phase 2a ongoing in Sjögren’s syndrome (Servier sponsor). - OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.
For more information: https://ose-immuno.com/en/
Click and follow us on Twitter and LinkedIn
https://twitter.com/OSEIMMUNO
https://www.linkedin.com/company/10929673
Contacts
Sylvie Détry sylvie.detry@ose-immuno.com +33 153 198 757 Investor Relations thomas.guillot@ose-immuno.com +33 607 380 431 | Media darren@lifescicomms.com +1 646 627 8387 French Media: FP2COM fportejoie@fp2com.fr +33 607 768 283 | gvanrenterghem@lifesciadvisors.com +41 76 735 01 31 |
Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of
These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the
Source:
2021 GlobeNewswire, Inc., source